Vaccinex sees long term value in building clinical programs that beneficially impact patient care. With that goal in mind, we are building a pipeline of novel candidate therapeutics that we hope will improve upon existing therapies and offer patient treatment options that improve their quality of life. Use the menu on the left to browse our clinical programs.



Active Clinical Trials

June – 2015 – Huntington’s Disease SIGNAL trial


A Phase 2, multi-center, randomized, double-blinded, placebo-controlled clinical trial in subjects with late prodromal and early manifest Huntington disease (HD) to assess safety, tolerability, pharmacokinetics, and efficacy of VX15/2503


Link to page for this study
Flyer with more information


February – 2018 – Vaccinex Sponsored a Key Opinion Leader (KOL) Luncheon on Huntington’s Disease


A Key Opinion Leader (KOL) Luncheon on Huntington’s Disease (HD) was hosted by Vaccinex on February 6, 2018.  The meetings featured presentations by Ira Shoulson, MD, (Georgetown University), Karl Kieburtz, MD, MPH (University of Rochester), and Maurice Zauderer, Ph.D. (Vaccinex, Inc.) who provided an update on the Company’s SIGNAL trial (Phase 2 study of investigational VX15/2503 antibody in HD). Discussion included recent research and the current treatment landscape, as well as the unmet medical need for treating patients with Huntington’s Disease.


To see and hear a replay of the KOL Luncheon, please click here to register or log in.